Efficient suicide gene therapy of transduced and distant untransduced ovary tumors is correlated with significant increase of intratumoral T and NK cells

Biomedicine and Pharmacotherapy

Volumn 54, Issue 10, 2000, Pages 479-486

  Nagy, H J ^a,c   Panis, Y ^a,d   Fabre, M ^b   Engelmann, C ^a   Soubrane, O ^a   Houssin, D ^a   Klatzmann, D ^a  

^a Université Paris V ^*  (France)

^b BICÊTRE HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Bystander; Ganciclovir; Gene therapy; Herpes simplex type 1 thymidine kinase gene; Rat ovarian cancer

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; VIRUS ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; RAT;

EID: 0033679287     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)00008-1     Document Type: Article

References (56)

1. Retroviral targeted delivery
2. Drug sensitivity ('suicide') genes for selective cancer chemotherapy
3. Gene therapy for cancer
4. The basic science of gene therapy
5. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
6. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors
7. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats
8. Regression of an established macroscopic liver tumor by in vivo retroviral-mediated transfer of a suicide gene
9. Are hepatomas a good target for suicide gene therapy? An experimental study in rats using retroviral-mediated transfer of thymidine kinase gene
10. Clinical applications of gene therapy for cancer
11. Gene therapy for metastatic malignant melanoma: Evaluation of tolerance to intratumoral injection of cells, producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration
12. Gene therapy for the treatment of brain tumors using intratumoral transduction with the thymidine kinase gene and intravenous ganciclovir
13. In situ use of suicide genes for cancer therapy
14. The treatment of ovarian cancer with a gene modified cancer vaccine: A phase 1 study
15. A phase 1 trial of in vivo gene therapy with thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer
16. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients
17. A new nucleoside analog, 9-[(2-hydroxy-1-[hydroxymethyl]ethoxy)-methyl] guanine, highly active in vitro against herpes simplex virus types 1 and 2
18. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro
19. The extent of heterocellular communication mediated by gap junctions is, predictive of bystander tumor cytotoxicity in vitro
20. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
21. Cancer gene therapy: A bystander effect using the gap junctional pathway
22. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells
23. 'Bystander killing' induces apoptosis and is inhibited by forskolin
24. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
25. Immune system in suicide gene therapy
26. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cells induces tumor-specific cytotoxic T cells in mice
27. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene
28. In vivo analysis of the 'bystander effect': A cytokine cascade
29. The role of cytokines in mediating the bystander effect using HSV-TK xenogenic cells
30. A 'distant' bystander effect of suicide gene therapy: Regression of nontransduced tumors together with a distant transduced tumor
31. The spread of ovarian cancer
32. Establishment and morphologic characterization of cell line (DMBA-OC-1) from 7,12-dimethylbenz(a)anthracene-induced rat ovarian carcinoma
33. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment
34. Analysis of tumor growth curves
35. The localization of populations of lymphocytes defined by monoclonal antibodies in rat lymphoid tissues
36. NKR-P1, a signal transduction molecule on natural killer cells
37. Macrophage heterogeneity in the rat as delineated by two monoclonal antobodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3
38. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene
39. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
40. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component
41. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors
42. Gene therapy of hepatoma: Bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir
43. Bystander tumoricidal effect in the treatment of experimental brain tumors
44. Bystander effect caused by suicide expression indicates the feasibility of gene therapy for hepatocellular carcinoma
45. Prodrug-activated gene therapy: Involvement of an immunological component in the 'bystander effect'
46. Preservation of the bystander cytocidal effect of irradiated herpes simplex virus thymidine kinase (HSV-tk) modified tumor cells
47. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes virus-thymidine kinase/ganciclovir paradigm
48. Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells
49. Suicide gene therapy of chemically induced mammary tumor in rat: Efficacy and distant bystander effect
50. Suicide gene therapy for plasma cell tumors
51. HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect
52. An HSVtk-mediated localand distant bystander effect in tumors of head and neck origin in athymic mice
53. C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells
54. Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid)
55. Natural killer cells and their precursors in mice with severe combined immunodeficiency
56. Ovarian tumor antigens as potential targets for immune gene therapy